| 摘要 |
<p>The phytocannabinoid tetrahydrocannabivarin (THCV, THV) for use in the protection of pancreatic islet cells, preferably beta cells, wherein the protection of pancreatic islet cells preferably maintains insulin production at levels which are able to substantially control or improve control of blood glucose levels in a patient. Preferably the protection of the pancreatic islet cells supports the treatment of diabetic or pre-diabetic patients wherein the patient may have or is pre-disposed to type I diabetes, type II diabetes or gestational diabetes. THCV for use in the treatment of type I diabetes or as an oral anti-diabetic medication are outlined. THCV for use as a GLP-1 (glucagon-like peptide-1) agonist class of medication is also provided. The THCV may be present as a synthetic or an isolated phytocannabinoid, as an extract from a cannabis plant or as a botanical drug substance. Preferably the THCV is substantially free from tetrahydrocannabinol (THC) and/or cannabidiol (CBD)</p> |
